Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study)

Status unconfirmed · Phase 3

Conditions studied: Extensive-Stage Small Cell Lung Cancer

In brief

This is a multinational, multicenter, randomized controlled, open-label, adaptive study to evaluate the efficacy of PaCE chemotherapy in chemotherapy naive subjects with extensive-stage SCLC. Eligible subjects will be stratified according to age, gender, and Eastern Cooperative Oncology Group (ECOG) performance status, and randomized in a 1:1 ratio to receive either PaCE or CE chemotherapy. The study design uses an adaptive group sequential approach with sample size re-estimation at the interim analysis. Secondary efficacy endpoints include ORR, PFS, duration of response and changes in QOL and disease-related symptoms. Tumor-related endpoints will be assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 guidelines. The safety of study treatments will be assessed by the frequency and severity of adverse events as determined by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03. To provide an initial confirmation of safety, an early interim analysis of safety data only will be performed. An independent Data Monitoring Committee (DMC) will be convened to assess the safety and efficacy of the study interventions and to monitor the overall conduct of the clinical trial.

Key facts

Study ID

NCT01555710

Run by

Alaunos Therapeutics

People needed

548

Starts

2012-05-01

Expected to finish

2015-06-01

Last updated by the study team

2013-05-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Documented extensive-stage small cell lung cancer.
• Patient has received no prior chemotherapy, adjuvant therapy, or radiotherapy for lung cancer.
• ECOG Performance Status of 0, 1 or 2.
• Adequate bone marrow and organ function based on the results of protocol- specified laboratory tests.
• Male and female patients must agree to use a highly reliable method of birth control during study participation.
• Able to provide informed consent

You may not qualify if…

• Previously untreated (non-irradiated), symptomatic brain metastases.
• Known allergy to any of the study drugs or their excipients.
• Any unstable or clinically significant concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a patient and/or their compliance with the protocol, based on screening tests, physical examination and medical history (as specifically defined in the clinical protocol).
• Any malignancy other than small cell lung cancer within the last 5 years prior to randomization, with the exception of cervical carcinoma in situ, nonmelanoma skin cancer, or superficial bladder tumors (Ta, Tis, or T1) that have been successfully and curatively treated with no evidence of recurrent or residual disease. (Exception: Subjects with a history of malignancy other than small cell lung cancer may be enrolled after consultation with the medical monitor provided the patient's prognosis is best defined by the extensive-stage small cell lung cancer).
• Currently pregnant or nursing.

Where it is running

• University of Southern California — Los Angeles, California, United States
• Redwood Regional Oncology Group — Santa Rosa, California, United States
• Christiana Care Health Services — Newark, Delaware, United States
• Baptist Cancer Institute — Jacksonville, Florida, United States
• Hematology Oncology Associates of the Treasure Coast — Port Sant Lucie, Florida, United States
• Peachtree Hematology Oncology Consultants — Atlanta, Georgia, United States
• Rush University Medical Center — Chicago, Illinois, United States
• Medical and Surgical Specialists, LLC — Galesburg, Illinois, United States
• Illinois Cancer Specialists — Niles, Illinois, United States
• Central Indiana Cancer Centers — Fishers, Indiana, United States
• Goshen Center for Cancer Care — Goshen, Indiana, United States
• Indiana University — Indianapolis, Indiana, United States
• Horizon Oncology Center — Lafayette, Indiana, United States
• Indiana University Health Ball Memorial Hospital — Muncie, Indiana, United States
• University of Kansas Hospital — Overland Park, Kansas, United States
• Central Baptist Hospital — Lexington, Kentucky, United States
• Medical Oncology, LLC — Baton Rouge, Louisiana, United States
• Frederick Memorial Hospital Regional Cancer Therapy Center — Frederick, Maryland, United States
• Metro Health Cancer Center — Wyoming, Michigan, United States
• Saint Mary's Medical Center — Duluth, Minnesota, United States
• Virginia Piper Cancer Institute — Minneapolis, Minnesota, United States
• John Theurer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey, United States
• Hematology Oncology Associates of Northern New Jersey, PA, Carol G. Simon Cancer Center — Morristown, New Jersey, United States
• University of New Mexico Cancer Center — Albuquerque, New Mexico, United States
• Birmingham Hematology and Oncology Associates, LLC — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.